Cholesteryl ester transfer protein TaqIB polymorphism and its association with serum lipid levels and longevity in Chinese Bama Zhuang population

Shang-Ling Pan1,2, Fei Wang2, Ze-Ping Lu3, Cheng-Wu Liu2, Cai-You Hu3, Huan Luo2, Jun-Hua Peng2, Xiao-Qiu Luo2, Guo-Fang Pang3, Shao-Hua Lu2, Hua-Yu Wu2, Ling-Jin Huang2 and Rui-Xing Yin1*

Abstract

Background: TaqIB polymorphism in the cholesteryl ester transfer protein (CETP) gene has been reported to be associated with serum high-density lipoprotein cholesterol (HDL-C) levels and longevity in several populations, but controversial results also arose probably due to racial/ethnic diversity. Bama is a remote and mountainous county located in the northwest of Guangxi, People’s Republic of China, which has been well known for its longevity for centuries. The current study was to investigate the possible association of CETP TaqIB polymorphism with serum lipid levels and longevity in the Bama Zhuang population.

Methods: The CETP TaqIB genotypes were determined by polymerase chain reaction and restriction fragment length polymorphism in 523 long-lived inhabitants (long-lived group, LG; aged 90-107 years) and 498 healthy controls without longevity family history (non-long-lived group, non-LG; aged 40-69 years) residing in Bama County.

Results: The levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were higher but TG, HDL-C/LDL-C ratio and the prevalence of dyslipidemia were lower in LG than in non-LG (P < 0.001 for all). There were no differences in the allelic and genotypic frequencies between the two groups (P > 0.05). Serum HDL-C levels and HDL-C/LDL-C ratio in LG were different among the genotypes (P < 0.01 for each), the subjects with B2B2 and B1B2 genotypes had higher HDL-C levels and HDL-C/LDL-C ratio than the subjects with B1B1 genotype, whereas the levels of TC and HDL-C in non-LG were different among/ between the genotypes (P < 0.01 for each), the B2 allele carriers had lower TC and higher HDL-C levels than the B2 allele noncarriers. Serum TG and HDL-C levels and HDL-C/LDL-C ratio were correlated with genotypes in LG, whereas serum TC and HDL-C levels were associated with genotypes in non-LG (P < 0.05-0.001).

Conclusions: The association of CETP TaqIB polymorphism and serum lipid profiles is different between LG and non-LG in the Chinese Bama Zhuang population. CETP TaqIB polymorphism might be one of the longevity-related genetic factors in this population.

Introduction

Cholesterol plays an essential physiological role in humans. It is mainly synthesized and esterified by the liver and then is secreted from the liver into plasma as very low density lipoprotein (VLDL), which gets converted to low density lipoprotein (LDL). In contrast, reverse cholesterol transport (RCT) mediates the conveyance of free unesterified cholesterol mobilized from peripheral cells and destined for disposal by the liver. In this process, cholesteryl ester transfer protein (CETP), a 74-kDa hydrophobic glycoprotein, facilitates the transfer of cholesterol ester from high density lipoprotein (HDL) to apolipoprotein (Apo) B-containing lipoproteins including VLDL and LDL, for disposal via the LDL receptor pathway in the liver, and of
triglyceride (TG) in the opposite direction in plasma [1,2]. Remarkably, these rationales indicate that CETP plays a significant role in the modulation of cholesterol.

In humans, CETP is expressed predominantly in the liver, spleen, and adipose tissue [1]. Detectable levels of CETP can also be seen in the small intestine, adrenal glands, heart, kidneys, or skeletal muscle [3]. The gene encoding CETP consists of 16 exons and 15 introns encompassing 25 kb on chromosome 16q12-21 adjacent to the lecithin-cholesterol acyltransferase gene [4]. To date, a number of common polymorphisms and rare variants at the CETP gene locus, such as I405V, D442G, I14A, A373P, R451Q, promoter polymorphism (Y629A/C, Y1337C/T and Y971G/A), which cause depletion of CETP activity and consequently high high-density lipoprotein cholesterol (HDL-C) in plasma, have been described across populations [5-8]. One of these common polymorphisms is TaqIB, a silent base change affecting the 277th nucleotide in the first intron of the CETP gene [4]. The B2 allele, absence of the TaqI restriction site, has been found to be associated with elevated plasma HDL-C level and reduced plasma CETP mass and activity and coronary heart disease (CHD) risk [9-12], and accordingly to be associated with longer life expectancy [13,14]. This hypothesis is further supported by the fact that high HDL-C levels are often observed in healthy elderly aged 85 and above [13,15]. However, inconsistent findings also arose in different studies, e.g., a positive association of HDL-C levels with increased CHD risk has been reported [16]; not all CETP deficiencies with high HDL-C levels are correlated with longevity [17]. These controversial results suggest that the roles of CETP gene variations in longevity appear much more complex than expected and need further elucidation.

Bama is a remote and mountainous county located in the northwest of Guangxi, People’s Republic of China. It has been well known for its longevity for centuries. The population size and centenarian rate in Bama County are around 240,000 and 30/100,000 respectively, according to the National Population Census of China in the past decades [18,19]. Although a number of studies involving natural environment, dietary habit, socioeconomic status and genetic background have been conducted for decades [19-22], the underlying mechanisms of the longevity in this county are still unknown. Genetically, the majority (> 85%) of the inhabitants living in Bama County belong to the north branch of Zhuang ethnic group. Zhuang is the largest minority in China with a total population of 15 millions [23,24]. Long-term geographic and social isolation as well as inbreeding result in both cultural and genetic homogeneity of Bama Zhuang branch, and therefore Bama Zhuang has become a useful subgroup for population genetic studies. We have initiated the Bama Longevity Genetic Study (BLGS) since late 1998. Several genetic polymorphisms such as human leukocyte antigen (HLA), ApoE, p53, and transforming growth factor-β1 (TGF-β1) genes and the haplotypes of mitochondria DNA [19,25-29] have been shown difference between long-lived group (LG) and non-long-lived group (non-LG), indicating that Bama long-lived individuals may have favorable genetic background for their survivals. Therefore, the aim of the present study was to determine the TaqIB polymorphism of CETP gene and its association with serum lipid levels and longevity in the Chinese Bama Zhuang population.

Materials and methods

Study population

A total of 523 long-lived subjects (339 females and 184 males, LG) with exceptional longevity residing in Bama County, Guangxi, People’s Republic of China were recruited to participate in the study, which was conducted from 2008 to 2011. The ages of the subjects ranged from 90 to 107 years, with an average age of 93.38 ± 3.09 years. The ages were defined by dates of birth as stated on identity cards. During the same period, a total of 498 healthy participants (253 males and 245 females, non-LG) without longevity family history were also randomly selected from the same area. The average age of the participants was 53.12 ± 8.86 years (range, 40-69 years). All study subjects were unrelated and belong to Zhuang ethnic group. They have been living in Bama rural area and doing farm work lifelong. All subjects were essentially healthy and had no evidence of any chronic illness, including hepatic, renal, or thyroid. The participants with a history of myocardial infarction, stroke, diabetes were also excluded. The participants were not taking medications known to affect serum lipid levels such as statins or fibrates, beta-blockers, diuretics, or hormones. The current study was approved by the Ethics Committee of Guangxi Medical University. Informed consent was obtained from all subjects after they received a full explanation of the study.

Epidemiological survey

Information on demography and lifestyle factors was collected with standardized questionnaires. The physical examination included blood pressure, body height, body weight, waist circumference, and body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters (kg/m²). Sitting blood pressure was obtained 3 times, using a standard mercury sphygmomanometer with the subject resting for at least 5 minutes, and the average of the 3 measurements was used for the level of blood pressure. Systolic blood pressure was determined by the first Korotkoff sound; and diastolic blood pressure, by the fifth Korotkoff sound. Hypertension was defined as an average systolic blood pressure of
140 mmHg or greater and an average diastolic blood pressure of 90 mmHg or greater, and/or self-reported pharmacological treatment for hypertension within the 2 weeks prior to the interview [30]. Normal weight, overweight, and obesity were defined as BMI < 24, 24 to 28, and > 28 kg/m², respectively [31].

Biochemical analysis

A venous blood sample of 8 mL was drawn from each subject after an overnight fasting. 4 mL of the sample was collected in a glass tube for serum lipid determination. The remaining sample was transferred to a tube with anticoagulant solution (4.80 g/L citric acid, 14.70 g/L glucose, and 13.20 g/L trisodium citrate) for DNA extraction. The levels of serum total cholesterol (TC), TG, HDL-C, and LDL-C in samples were determined by enzymatic methods with commercially available kits, Tcho-I, TGLH (Randox Laboratories Ltd, Crumlin, Antrim, United Kingdom), Cholestest N HDL, and Cholestest LDL (Daichichi Pure Chemicals Co, Ltd., Tokyo, Japan), respectively. All determinations were performed by standard automated methods with a biochemical analyzer (Type 7170A; Hitachi Ltd, Tokyo, Japan) at the Clinical Science Experiment Center of the First Affiliated Hospital, Guangxi Medical University. The normal ranges of serum TC, TG, HDL-C, and LDL-C levels in the Center were 3.10-5.17, 0.56-1.70, 0.91-1.81, and 1.70-3.20 mmol/L, respectively. The individuals with TC > 5.17 mmol/L and/or TG > 1.70 mmol/L were defined as hyperlipidemic [32].

DNA amplification and genotyping

Genomic DNA was isolated from peripheral blood leukocytes by standard methods [33]. Genotyping of the CETP TaqIB was performed as described previously [34] basing on the protocol introduced by Fumeron et al. [35]. Briefly, a 535 bp fragment in intron 1 of the CETP gene was amplified by polymerase chain reaction (PCR), with use of the following primers: F: 5’-CTGAGGGGATTGC-3’ and R: 5’-CTGAGGGGATTGC-3’. (Sangon Biotech Co., Ltd., Shanghai, People’s Republic of China). PCR was performed in a volume of 20 μL containing 200 ng of genomic DNA, plus 10 μL of Taq MasterMix (Beijing CoWin Bioscience Co., Ltd. People’s Republic of China), 6.25 μM (1.0 μL) of each primer, 7 μL ddH₂O and 1 U of DNA polymerase (Takara Biotechnology Co, Ltd, Dalian, People’s Republic of China). The cycle profile was as follows: pre-denaturation at 94°C for 2 min, followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 63°C for 30 s, and extension at 72°C for 30 s, with a final extension at 72°C for 5 min. The PCR products (8 μL) were digested with TaqI (0.2 U) restriction endonuclease (Takara Biotechnology Co, Ltd, Dalian, People’s Republic of China) at 65°C for 4 h, and the fragments were separated by electrophoresis in a 2% agarose gel for 45 min at 80 V. The target DNA fragments were 174- and 361-bp for the B1 allele and 535 bp for the B2 allele. The genotypes were identified and named according to the presence or absence of the enzymatic restriction sites, i.e. bands at 535-, 361-, and 174-bp for B1B2 heterozygotic genotype, 361- and 174-bp for B1B1 homozygotic genotype, and 535 bp for B2B2 homozygotic genotype. Laboratory technicians were masked to clinical and biochemical data.

Statistical analyses

Levels of the quantitative variables are presented as mean ± SD (serum TG levels are presented as medians and interquartile ranges). Hardy-Weinberg equilibrium was computed for the expected genotype distribution. Allelic and genotypic frequencies were calculated directly. Comparison of mean values of general characteristics between study groups was performed with the student unpaired t test and One-way ANOVA test. The statistical evaluation for the categorical variables was based on the calculation of the chi-square and Fisher’s exact criteria. The association of CETP TaqIB genotypes with serum lipid variables was tested by analysis of covariance. In order to assess the association of serum lipid levels with genotypes (B1B1 = 1, B1B2 = 2 and B2B2 = 3), multivariable linear regression analyses with stepwise modeling were also performed in the combined population of LG and non-LG, LG, non-LG; respectively. All tests were two-sided and P-values of 0.05 were considered significant. Data were analyzed using the statistical software package SPSS 13.0 (SPSS Inc, Chicago, IL).

Results

General characteristics and serum lipid levels

A summary of demographic, clinical, and biochemical characteristics of LG and non-LG is provided in Table 1. BMI was lower in LG as compared to non-LG (P < 0.001). The levels of systolic blood pressure and diastolic blood pressure were significantly higher in LG than in non-LG (P < 0.001 for all). The levels of TC, HDL-C, and LDL-C were markedly higher, while TG, HDL-C/LDL-C ratio as well as the prevalence of dyslipidemia were lower in LG as compared with non-LG (P < 0.001 for all).

Genotypic and allelic frequencies

The CETP TaqIB genotype and allele frequencies are shown in Table 2. The dominant allele was B1, and the dominant genotypes were B1B2 and B1B1 in both groups. Homozygotic B2B2 genotype only accounted for approximately 10% in the studied participants. No significant difference was observed in the distribution of genotypes and alleles between the two groups (both P > 0.05), albeit the frequency of B2 allele was slightly higher in the longevity group as compared with the counterparts.
Genotypes and serum lipid levels
As shown in Table 3, the levels of HDL-C and the ratio of HDL-C to LDL-C in LG were different among the genotypes (P < 0.01 for each), the subjects with B2B2 and B1B2 genotypes had higher HDL-C levels and HDL-C/LDL-C ratio than the subjects with B1B1 genotype, whereas the levels of TC and HDL-C in non-LG were different among/between the genotypes (P < 0.01 for each), the B2 allele carrier sh a dl ower TC and higher HDL-C levels than the B2 allele noncarriers. When the association of CETP TaqIB polymorphism and serum lipid levels was stratified by gender, we found that serum TC, TG, and HDL-C levels in the combined population were different among the genotypes in males (P < 0.05-0.001), and HDL-C and LDL-C levels were different among the genotypes in females (P < 0.01 and P < 0.05; respectively; Table 4). Serum HDL-C levels in LG were different among the genotypes in males (P < 0.05-0.001), and HDL-C and TC levels were different among the genotypes in females (P < 0.01, and P < 0.05) but not in females (Table 5). Serum HDL-C levels in non-LG were different among the genotypes in males (P < 0.001), and TC, HDL-C and LDL-C levels were different among the genotypes in females (P < 0.05-0.001; Table 6).

Correlation between serum lipid parameters and genotypes
Multiple linear regression analysis showed that serum TG and HDL-C levels and HDL-C/LDL-C ratio were correlated with genotypes in LG, whereas serum TC and HDL-C levels were associated with genotypes in non-LG (P < 0.05-0.001; Table 7).

Discussion
TaqIB is one of the common polymorphisms of the CETP gene. In the current study, the overall frequency of B2 allele was 0.372 (0.384 in LG and 0.345 in non-LG), similar to our previous finding in Hei Yi Zhuang, another Zhuang subgroup resides in Napo, a county bordering northwest Vietnam [34,36], and to the result from different populations, such as Han Chinese (0.39), Vietnamese (0.34), and Korean (0.36) [37-39], but lower than that in Caucasians (0.40-0.64) [14,40], Jews and Japanese [17,41,42]. The considerable high frequency of B2 mutation across populations worldwide appears to imply that the origin of B2 can at least be traced back long before the differentiation of major ethnic groups for some selective reasons. We did not observe significant difference in genotypic and allelic frequencies of CETP TaqIB polymorphism between the two groups; this was in agreement with those of the Japanese centenarian study [13,17]. However, there was a trend that the frequencies of B1 allele and B1B1 genotype in long-lived individuals was slightly lower than those in non-long-lived subjects, or conversely, the B2 allele tended to enrich in the elderly old. This observation seems to imply that the evolution of B2 allele may be favorable for the survivals of modern human beings whose living environment and dietary structure have been changing tremendously, at least in Bama area.

### Table 1 Clinical characteristics and serum lipid profiles between LG and non-LG

| Parameter               | LG (n = 523) | non-LG (n = 498) | t (χ²) | P     |
|-------------------------|--------------|-----------------|--------|-------|
| Age (years)             | 93.38 ± 3.06 | 53.12 ± 8.86    | 96.088 | 0.000 |
| Gender (M/F)            | 184/339      | 253/245         | 25.428 | 0.000 |
| Body mass index (kg/m²) | 20.22 ± 3.52 | 22.14 ± 3.67    | -8.521 | 0.000 |
| Systolic blood pressure (mmHg) | 166.14 ± 28.04 | 131.31 ± 20.23 | 22.844 | 0.000 |
| Diastolic blood pressure (mmHg) | 89.33 ± 13.48 | 85.24 ± 11.43 | 5.240  | 0.000 |
| Total cholesterol (mmol/L) | 5.13 ± 1.01  | 4.87 ± 0.96     | 4.177  | 0.000 |
| Triglyceride (mmol/L)   | 0.97 (0.47)  | 1.08 (0.86)     | -3.256 | 0.001 |
| HDL-C (mmol/L)          | 1.60 ± 0.35  | 1.51 ± 0.29     | 4.968  | 0.000 |
| LDL-C (mmol/L)          | 3.04 ± 0.87  | 2.69 ± 0.89     | 6.427  | 0.000 |
| HDL-C/LDL-C ratio       | 0.57 ± 0.24  | 0.67 ± 0.59     | -3.466 | 0.001 |
| Dyslipidemia (n [%])    | 66(12.62)    | 94(18.88)       | -7.555 | 0.000 |

### Table 2 Genotype and allele frequencies of the CETP TaqIB polymorphism in LG and non-LG [n (%)]

| Groups    | n   | Genotype       | Allele       |
|-----------|-----|----------------|--------------|
|           |     | B1B1           | B1B2         | B2B2         | B1   | B2   |
| LG        | 523 | 187 (35.8)     | 270 (51.6)   | 66 (12.6)    | 644  (61.6) | 402 (38.4) |
| Non-LG    | 498 | 206 (41.4)     | 240 (48.2)   | 52 (10.4)    | 652  (65.5) | 344 (34.5) |
| χ²        | -   | 3.734          |              |              | 3.336 |      |
| P         | -   | 0.155          |              |              | 0.068 |      |

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. The value of triglyceride was presented as median (interquartile range), the difference between the two groups was determined by the Wilcoxon-Mann-Whitney test.

Pan et al. Lipids in Health and Disease 2012, 11:26
http://www.lipidworld.com/content/11/1/26
It has been established that HDL-C is an independent risk factor for CHD [43]. A growing body of evidences demonstrate that elevated levels of HDL-C may reduce CHD risk and thus contribute to longer life expectancy [13]. We also found higher HDL-C and LDL-C levels in the long-lived subjects as compared to general populations. Moreover, this raised HDL-C was associated with B2 allele and B2B2 genotype, which was consistent with Table 3 Comparison of serum lipid levels among the genotypes between the two groups

| Group | Genotype | n  | TC (mmol/L) | TG (mmol/L) | HDL-C (mmol/L) | LDL-C (mmol/L) | HDL-C/LDL-C |
|-------|----------|----|------------|-------------|----------------|----------------|-------------|
| LG    | B1B1     | 187| 5.16 ± 1.00| 1.03(0.59)  | 1.54 ± 0.31b  | 3.11 ± 0.84b   | 0.53 ± 0.17  |
|       | B1B2     | 270| 5.09 ± 1.02| 0.95(0.44)  | 1.63 ± 0.37b  | 3.01 ± 0.89b   | 0.60 ± 0.26  |
|       | B2B2     | 66 | 5.17 ± 0.99| 0.97(0.41)  | 1.67 ± 0.35b  | 2.99 ± 0.88b   | 0.62 ± 0.28  |
| F     | -        | -  | 0.283      | 3.845        | 4.868          | 0.867          | 6.592       |
| P     | -        | -  | 0.753      | 0.146        | 0.008          | 0.421          | 0.001       |
| B1B1  | 187      |    | 5.16 ± 1.00| 1.03(0.59)  | 1.54 ± 0.31b  | 3.11 ± 0.84b   | 0.53 ± 0.17  |
| B1B2/B2B2 | 336    |    | 5.11 ± 1.01| 0.95(0.43)  | 1.64 ± 0.37a  | 3.00 ± 0.89b   | 0.60 ± 0.27  |

Table 4 Comparison of clinical characteristics and serum lipid levels among the genotypes stratified by gender in overall population

| Parameter            | B1B1     | B1B2     | B2B2     | F       | P       |
|----------------------|----------|----------|----------|---------|---------|
| Male/n               | 166      | 224      | 47       | -       | -       |
| Age (years)          | 70.15 ± 21.11 | 68.85 ± 21.37 | 69.62 ± 23.38 | 0.177   | 0.838   |
| Body mass index (kg/m²) | 21.48 ± 3.35 | 21.58 ± 3.43 | 21.17 ± 4.04 | 0.285   | 0.752   |
| Systolic blood pressure (mmHg) | 146.767 ± 26.80 | 142.51 ± 27.92 | 144.98 ± 26.29 | 1.169   | 0.312   |
| Diastolic blood pressure (mmHg) | 88.76 ± 12.64 | 85.90 ± 11.89 | 88.04 ± 14.55 | 2.615   | 0.074   |
| Total cholesterol (mmol/L) | 4.937 ± 1.09 | 4.88 ± 1.00 | 5.36 ± 1.12 | 4.237   | 0.015   |
| Triglyceride (mmol/L) | 1.08(0.67) | 0.95(0.78) | 1.18(0.74) | 7.329   | 0.026   |
| HDL-C (mmol/L)       | 1.47 ± 0.30 | 1.57 ± 0.33 | 1.71 ± 0.36 | 10.803  | 0.000   |
| LDL-C (mmol/L)       | 2.85 ± 0.96 | 2.74 ± 0.94 | 2.86 ± 0.93 | 0.788   | 0.455   |
| HDL-C/LDL-C          | 0.66 ± 0.89 | 0.67 ± 0.34 | 0.68 ± 0.33 | 0.010   | 0.990   |
| Female/n             | 227      | 286      | 71       | -       | -       |
| Age (years)          | 73.93 ± 21.91 | 78.76 ± 19.30 | 79.56 ± 18.62 | 4.249   | 0.015   |
| Body mass index (kg/m²) | 21.24 ± 3.35 | 20.47 ± 3.30 | 21.59 ± 3.70 | 3.777   | 0.023   |
| Systolic blood pressure (mmHg) | 150.42 ± 29.39 | 154.15 ± 33.03 | 154.17 ± 32.08 | 0.972   | 0.379   |
| Diastolic blood pressure (mmHg) | 88.18 ± 12.45 | 86.59 ± 13.09 | 88.35 ± 12.78 | 1.188   | 0.030   |
| Total cholesterol (mmol/L) | 4.99 ± 0.92 | 5.12 ± 0.96 | 4.88 ± 0.93 | 2.392   | 0.092   |
| Triglyceride (mmol/L) | 1.07(0.80) | 1.00(0.49) | 1.00(0.60) | 2.739   | 0.254   |
| HDL-C (mmol/L)       | 1.50 ± 0.30 | 1.59 ± 0.35 | 1.62 ± 0.29 | 5.739   | 0.003   |
| LDL-C (mmol/L)       | 2.87 ± 0.85 | 3.02 ± 0.86 | 2.74 ± 0.84 | 3.810   | 0.023   |
| HDL-C/LDL-C          | 0.57 ± 0.23 | 0.58 ± 0.29 | 0.66 ± 0.29 | 2.954   | 0.053   |

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. The value of triglyceride was presented as median (interquartile range), the difference among the genotypes was determined by the Kruskal-Wallis Test. 

Pan et al. Lipids in Health and Disease 2012, 11:26
http://www.lipidworld.com/content/11/1/26
some previous reports [12,14,34,44-46], but not others [17,47]. It is widely accepted that B2 allele carriers exhibit lower CETP levels and/or activity, leading to a dysfunction of the reverse cholesterol transport, causing an accumulation of cholesterol ester in HDL style and thus increasing the levels of HDL-C. The mechanism by which TaqIB polymorphism may affect CETP activity or HDL-C levels is not well known. Because this

### Table 5 Comparison of clinical characteristics and serum lipid levels among genotypes stratified by gender in LG

| Parameter                      | B1B1  | B1B2  | B2B2  | F    | P     |
|-------------------------------|-------|-------|-------|------|-------|
| Male/n                        | 70    | 91    | 23    | -    | -     |
| Age (years)                   | 93.61 ± 3.43 | 93.17 ± 2.68 | 92.61 ± 2.73 | 1.081 | 0.341 |
| Body mass index (kg/m²)       | 20.82 ± 3.70 | 20.30 ± 3.30 | 20.30 ± 5.05 | 0.426 | 0.654 |
| Systolic blood pressure (mmHg) | 164.79 ± 26.08 | 162.59 ± 27.50 | 161.22 ± 23.48 | 0.213 | 0.808 |
| Diastolic blood pressure (mmHg)| 88.60 ± 13.55 | 89.14 ± 13.73 | 88.70 ± 13.65 | 0.034 | 0.967 |
| Total cholesterol (mmol/L)    | 4.97 ± 1.07 | 4.96 ± 1.09 | 5.30 ± 1.05 | 0.96 | 0.385 |
| Triglyceride (mmol/L)         | 0.93(0.37) | 0.91(0.32) | 1.03(0.41) | 5.025 | 0.052 |
| HDL-C (mmol/L)                | 1.52 ± 0.33 | 1.65 ± 0.39 | 1.73 ± 0.44 | 3.768 | 0.025 |
| LDL-C (mmol/L)                | 2.98 ± 0.93 | 2.89 ± 0.94 | 3.01 ± 0.96 | 0.244 | 0.784 |
| HDL-C/LDL-C                   | 0.66 ± 0.89 | 0.67 ± 0.34 | 0.68 ± 0.33 | 0.010 | 0.990 |

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. The value of triglyceride was presented as median (interquartile range), the difference among the genotypes was determined by the Kruskal-Wallis Test.

### Table 6 Comparison of clinical characteristics and serum lipid levels among genotypes stratified by gender in non-LG

| Parameter                      | B1B1  | B1B2  | B2B2  | F    | P     |
|-------------------------------|-------|-------|-------|------|-------|
| Male/n                        | 96    | 133   | 24    | -    | -     |
| Age (years)                   | 53.04 ± 8.00 | 52.21 ± 8.95 | 47.58 ± 7.11 | 4.044 | 0.019 |
| Body mass index (kg/m²)       | 21.96 ± 3.25 | 22.46 ± 3.24 | 22.00 ± 3.26 | 21.44 ± 4.25 | 3.970 | 0.020 |
| Systolic blood pressure (mmHg) | 167.16 ± 27.44 | 167.87 ± 29.84 | 168.47 ± 28.78 | 0.038 | 0.962 |
| Diastolic blood pressure (mmHg)| 91.08 ± 13.38 | 88.04 ± 13.40 | 91.84 ± 13.21 | 2.526 | 0.082 |
| Total cholesterol (mmol/L)    | 5.27 ± 0.94 | 5.16 ± 0.98 | 5.10 ± 0.96 | 0.645 | 0.525 |
| Triglyceride (mmol/L)         | 1.09(0.76) | 1.00(0.51) | 0.95(0.41) | 2.923 | 0.232 |
| HDL-C (mmol/L)                | 1.55 ± 0.30 | 1.62 ± 0.37 | 1.64 ± 0.30 | 1.603 | 0.203 |
| LDL-C (mmol/L)                | 3.19 ± 0.77 | 3.07 ± 0.86 | 2.97 ± 0.84 | 1.255 | 0.287 |
| HDL-C/LDL-C                   | 0.57 ± 0.23 | 0.58 ± 0.37 | 0.68 ± 0.33 | 0.010 | 0.990 |

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. The value of triglyceride was presented as median (interquartile range), the difference among the genotypes was determined by the Kruskal-Wallis Test.
Table 7 Correlation between serum lipid parameters and the CETP TaqIB polymorphism in LG and non-LG

| Lipid plus non-LG | Relative factor | Unstandardized coefficient | Standard error | Standardized coefficient | t | P |
|------------------|----------------|---------------------------|----------------|-------------------------|---|---|
| HDL-C            | Genotype       | 0.080                     | 0.015          | 0.160                   | 5.316 | 0.000 |
| LG               |                |                           |                |                         |    |    |
| TG               | Genotype       | -0.064                    | 0.029          | -0.093                  | -2.191 | 0.029 |
| HDL-C            | Genotype       | 0.074                     | 0.023          | 0.138                   | 3.219 | 0.001 |
| HDL-C/LDL-C      | Genotype       | 0.054                     | 0.016          | 0.149                   | 3.464 | 0.001 |
| Non-LG           |                |                           |                |                         |    |    |
| TC               | Genotype       | 0.132                     | 0.065          | 0.089                   | 2.030 | 0.043 |
| HDL-C            | Genotype       | 0.084                     | 0.019          | 0.189                   | 4.435 | 0.000 |

polymorphism located in an intron of the CETP gene which is unlikely to exhibit any functional effect. Given the reported associations of the B2 allele with increased CETP mass and/or activity, the most putative explanation is that this polymorphism is in linkage disequilibrium with some unknown functional mutations in the regulatory region of the CETP gene which might interact with each other to determine the HDL-C levels [45,48].

Some investigators suggested that TaqIB polymorphisms were solely associated with HDL-C levels, without being influenced by factors such as smoking, alcohol consumption and BMI [49], but most researchers believed that the association between TaqIB polymorphisms and HDL-C levels might be greatly affected by dietary habits, smoking, obesity, gender, and ethnic groups, etc. [34,50-52]. In the present study, we also showed that the association of CETP TaqIB polymorphism and serum lipid profiles is different between LG and non-LG, or between males and females in the Chinese Bama Zhuang population. The subjects with B2B2 and B2B1 genotypes in LG had higher HDL-C levels than the subjects with B1B1 genotype, whereas the B2 allele carriers in non-LG had lower HDL-C levels than the B2 allele noncarriers. The levels of HDL-C in LG were different among the genotypes in males but not in females. The levels of HDL-C in non-LG were different among the genotypes in males, whereas the levels of TC, HDL-C and LDL-C were different among the genotypes in females. The reason for this discrepancy is not well known. Thus, to better define the exact association of TaqIB polymorphisms with serum HDL-C levels and CHD, further studies are required in large populations.

Conclusion

The current study shows that the genotypic and allelic frequencies of CETP TaqIB polymorphism were not different between LG and non-LG, but the association of CETP TaqIB polymorphism and serum lipid profiles is different between the two groups in the Chinese Bama Zhuang population. The B2 allele and B2B2 genotype were associated with high HDL-C levels. Thus, CETP TaqIB polymorphism might be one of the longevity-related genes in this population.

Acknowledgements

We especially thank all of those who donated samples. This study was supported by the National Natural Science Foundation of China (No. 30860126, 31160209) and the Natural Science Foundation of Guangxi (No. GKQ0991033, GKZ0728160).

Author details

1Department of Cardiology, Institute of Cardiovascular Diseases, the First Affiliated Hospital, Guangxi Medical University, 22 Shuangyong Road, Nanning 530021, Guangxi, People’s Republic of China. 2Department of Pathophysiology, School of Premedical Sciences, Guangxi Medical University, Nanning 530021, Guangxi, People’s Republic of China. 3Department of Neurology, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, 85 Hedi Road, Nanning 530021, Guangxi, People’s Republic of China.

Authors’ contributions

SLP participated in the design, undertook genotyping, and drafted the manuscript. FW, CWL, JHP, XQL, SHL, HYW and LJH helped with genotyping. ZPL, CYH, HL and GFP took part in the epidemiological survey and collected the samples. RKY conceived the study, participated in the design, carried out the epidemiological survey, collected the samples, and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 21 January 2012 Accepted: 15 February 2012
Published: 15 February 2012

References

1. Tall A. Plasma lipid transfer proteins. Annu Rev Biochem 1995, 64:235-257.
2. Bruce C, Sharp DS, Tall AR. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res 1998, 39:1071-1078.
3. Bruce C, Chouinard RA Jr. Tall AR. Plasma lipid transfer proteins, high density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 1998, 18:297-330.
4. Drayna D, Jaragnin AS, McLean J, Henzel W, Kohr W, Fielding C, Lavin R. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987, 27:632-634.
5. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Matumasa Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990, 323:1234-1238.
6. Ageholm-Larsen B, Tybjerg-Hansen A, Schnoor P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations,
decreased HDL cholesterol, and possible decreased risk of ischemic heart disease. The Copenhagen City Heart Study. Circulation 2000, 102:2197-2203.

7. Frisvold E, Rinken AH, Le Goff W, Tanck MW, Lagarde JP, Jukema JW, Kastelein JJ, Chapman MJ, Guerin M: Functional interaction between -629 C/A, -971 G/A and -1337 C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. Hum Mol Genet 2005, 14:2607-2618.

8. Yijiang Z, Ruixing Y, Yiyang L, Yaju D, Shangling P, Weixiong L, Dezhai Y: Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with serum lipid levels in the Guangxi Hei Yi Zhuang and Han populations. JInvestig Med 2008, 56:847-857.

9. Freeman DJ, Packard CJ, Shepherd J, Gaffney D: On the Bama longevity zone and the local environment for centenarians in Bama. Chin J Epidemiol 2008, 29:575-581.

10. Kark JD, Sinnreich R, Leitersdorf E, Friedlander Y, Shpitzen S, Luci G: Association of cholesteryl ester transfer protein TaqIB B2B2 genotype is associated with higher HDL cholesterol and five-year survival in elderly people. J Atheroscler Thromb 2001, 8:151-156.

11. Kondo I, Berg K, Drayna D, Lawn R: Polymorphism of the cholesteryl ester transfer protein gene coding for cholesteryl ester transferprotein are related to plasma high-density lipoprotein cholesterol and transfer protein activity. Clin Sci 1990, 79:575-581.

12. Kostakou P, Kolovou V, Kolovou G, Stamatelatou M, Anagnostopoulou K, Kostakou P: CETP gene variation: relation to lipid parameters and cardiovascular risk. Curr Opin Lipidol 2004, 15:393-398.

13. Liang JY, Hu CY, Lu ZP, Li ZJ, Huang PY, Li BX, Yang YY: Polymorphisms and variations in lipid levels in patients with coronary artery disease. Chin J Cardiol 2006, 25:349-352.

14. Li Y, Jin L, Huang B, Liu C, Huang G, Ling B, Shen J, Jin L: The association of mitochondrial DNA haplogroup with human longevity in Guangxi Bama area. Chin J Gerontol 2004, 24:17-19.

15. Liu CW, Luo XQ, Lin WX, Yin RX, Lu ZP, Pan SL: Polymorphism of the transforming growth factor-β1 gene of Zhuang population in Guangxi Bama area and Hezhou area. Shandong Med J 2009, 49:17-19.

16. Liu CW, Luo XQ, Lin WX, Yin RX, Lu ZP, Pan SL: Polymorphism of the transforming growth factor-β1 gene of Zhuang population in Guangxi Bama area and Hezhou area. Shandong Med J 2009, 49:17-19.

17. Liu CW, Luo XQ, Lin WX, Yin RX, Lu ZP, Pan SL: Polymorphism of the transforming growth factor-β1 gene of Zhuang population in Guangxi Bama area and Hezhou area. Shandong Med J 2009, 49:17-19.

18. Liu CW, Luo XQ, Lin WX, Yin RX, Lu ZP, Pan SL: Polymorphism of the transforming growth factor-β1 gene of Zhuang population in Guangxi Bama area and Hezhou area. Shandong Med J 2009, 49:17-19.

19. Liu CW, Luo XQ, Lin WX, Yin RX, Lu ZP, Pan SL: Polymorphism of the transforming growth factor-β1 gene of Zhuang population in Guangxi Bama area and Hezhou area. Shandong Med J 2009, 49:17-19.

20. Liu CW, Luo XQ, Lin WX, Yin RX, Lu ZP, Pan SL: Polymorphism of the transforming growth factor-β1 gene of Zhuang population in Guangxi Bama area and Hezhou area. Shandong Med J 2009, 49:17-19.

21. Liu CW, Luo XQ, Lin WX, Yin RX, Lu ZP, Pan SL: Polymorphism of the transforming growth factor-β1 gene of Zhuang population in Guangxi Bama area and Hezhou area. Shandong Med J 2009, 49:17-19.

22. Liu CW, Luo XQ, Lin WX, Yin RX, Lu ZP, Pan SL: Polymorphism of the transforming growth factor-β1 gene of Zhuang population in Guangxi Bama area and Hezhou area. Shandong Med J 2009, 49:17-19.

23. Liu CW, Luo XQ, Lin WX, Yin RX, Lu ZP, Pan SL: Polymorphism of the transforming growth factor-β1 gene of Zhuang population in Guangxi Bama area and Hezhou area. Shandong Med J 2009, 49:17-19.

24. Liu CW, Luo XQ, Lin WX, Yin RX, Lu ZP, Pan SL: Polymorphism of the transforming growth factor-β1 gene of Zhuang population in Guangxi Bama area and Hezhou area. Shandong Med J 2009, 49:17-19.

25. Liu CW, Luo XQ, Lin WX, Yin RX, Lu ZP, Pan SL: Polymorphism of the transforming growth factor-β1 gene of Zhuang population in Guangxi Bama area and Hezhou area. Shandong Med J 2009, 49:17-19.

26. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

27. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

28. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

29. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

30. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

31. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

32. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

33. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

34. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

35. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

36. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

37. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

38. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

39. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

40. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

41. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

42. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.

43. Packard CJ, Saito Y: Polymorphism of HLA-DRB1 locus of the Zhuang longevous elderly in Bama County of Guangxi. Chin J Gerontol 2008, 28:365-367.
levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 2002, 22:1148-1154.

45. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, Lahoz C, Coltell O, Wilson PW, Schaefer EJ. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000, 20:1323-1329.

46. Ozsait B, Komurcu Bayrak E, Poda M, Can G, Ilgenc G, Onat A, Humphries SE, Erginli Unaltuna N. CETP TaqIB polymorphism in Turkish adults: association with dyslipidemia and metabolic syndrome. Anadolu Kardiyol Derg 2008, 8:324-330.

47. Kuivenhoven JA, Jukema JW, Zwierdeman AH, de Knijff P, McPherson R, Brusche AV, Lie KL, Kastelein JJ. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998, 338:86-93.

48. Junyent M, Lee YC, Smith CE, Arnett DK, Tsai MY, Kabagambe EK, Straka RJ, Province M, An P, Lai CQ, Pamell LD, Shen J, Bonecki L, Ordovas JM. The effect of a novel intergenic polymorphism (rs11774572) on HDL-cholesterol concentrations depends on TaqIB polymorphism in the cholesteryl ester transfer protein gene. Nutr Metab Cardiovasc Dis 2010, 20:34-40.

49. Corella D, Sáez C, Guillén M, Portalés O, Mulet F, González JM, Ordovás JM. Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. Atherosclerosis 2000, 152:567-576.

50. Freeman DJ, Griffin BA, Holmes AP, Lindsay GM, Gaffney D, Packard CJ, Shepherd J. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the Taq I B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb 1994, 14:336-344.

51. Corella D, Carrasco P, Amiano P, Arrigo L, Chirlaque MD, Huerta JM, Martínez C, Martínez-Cambor P, Molina E, Navarro C, Quirós JR, Rodríguez L, Sánchez MJ, Ortega-Azorín C, Ros E, Sala S, González CA, Moreno C. Common cholesteryl ester transfer protein gene variation related to high-density lipoprotein cholesterol is not associated with decreased coronary heart disease risk after a 10-year follow-up in a Mediterranean cohort: Modulation by alcohol consumption. Atherosclerosis 2010, 211:531-538.

52. Dedoussis GV, Panagiotakos DB, Lousiou E, Mantoglou I, Chrysoghoou C, Lamiou K, Pitsavos C, Stefanadis C. Cholesteryl ester transfer protein (CETP) polymorphism and the association of acute coronary syndromes by obesity status in Greek subjects: the CARDIO2000-GENE study. Hum Hered 2007, 63:155-161.

doi:10.1186/1476-511X-11-26

Cite this article as: Pan et al. Cholesteryl ester transfer protein TaqIB polymorphism and its association with serum lipid levels and longevity in Chinese Bama Zhuang population. Lipids in Health and Disease 2012 11:26.